Eyenovia strengthens balance sheet with a $15 million institutional capital investment from armistice capital master fund ltd.

New york, march 04, 2022 (globe newswire) -- eyenovia, inc. (nasdaq: eyen), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (map™) therapeutics, today announced that the company has entered into a securities purchase agreement with armistice capital master fund ltd., a leading health care investor, in an offering of 3,000,000 shares of its common stock pre-funded warrants to purchase up to 1,870,130 shares of its common stock, and common warrants to purchase up to 4,870,130 shares of its common stock (the "offering"). the shares of common stock and the pre-funded warrants are each being sold in combination with corresponding common warrants. the aggregate offering price for each share of common stock or each pre-funded warrant and, in each case, the accompanying common warrant is $3.08, which was the market price of the common stock as of the close of trading on march 3, 2022.
EYEN Ratings Summary
EYEN Quant Ranking